Medical-device giant Medtronic announced a multibillion-dollar restructuring program Monday that will impact an undisclosed number of employees.
The company discussed its plan at the J.P. Morgan Healthcare Conference on Monday and unveiled some details in a Securities and Exchange Commission filing. Medtronic expects the plan to result in more than $3 billion in annual gross savings by the end of its 2022 fiscal year.
The restructuring will affect an undisclosed number of employees, but Medtronic’s total employee count will hold steady, the company said in an SEC filing. Medtronic has about 9,000 employees in Minnesota and is among the state’s largest employers.
“The company expects that its overall employee base will remain relatively unchanged, as new jobs are created in new capability areas and resources are deployed to support the company’s growing market needs,” Medtronic said in a regulatory filing.
Medtronic expects to record charges of between $1.6 billion and $1.8 billion over a five-year period as a result of the restructuring, which it named “Enterprise Excellence Program.” Between 40 and 50 percent of those charges will be tied to employee-related costs, including severance expenses.
Medtronic cut an undisclosed number of jobs at its operations in Memphis over the summer, and said in August it would lay off 185 workers in Illinois after closing a distribution center. A company spokesman told MassDevice that Medtronic has more than 4,000 open positions.
Medtronic unveiled some of the program’s goals — such as improving productivity and integrating manufacturing systems — but few details.
“The program is designed to drive operating margin improvement as well as fund investment in strategic growth initiatives,” the company said in the regulatory filing.
Dublin-based Medtronic’s operational headquarters in Fridley.
By Katharine Grayson
Source: Biz Journal Minneapolis
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.